Search research articles
Contact Us
Filters
Showing results (51-60 of 58) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 58 results.
ESMO Open
|
May 1, 2025
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)
R Galot, C Le Tourneau, L Licitra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 23, 2019
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages
C A Gomez-Roca, A Italiano, C Le Tourneau, et al.
ESMO Open
|
June 12, 2021
Prognostic value of tumor mutational burden in patients with oral cavity squamous cell carcinoma treated with upfront surgery
A Moreira, A Poulet, J Masliah-Planchon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 7, 2025
ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice
C B Westphalen, L Boscolo Bielo, P Aftimos, et al.
British Journal of Cancer
|
April 26, 2014
Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial
C Le Tourneau, X Paoletti, N Servant, et al.
ESMO Open
|
April 17, 2021
Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial
E de Guillebon, M Jimenez, L Mazzarella, et al.
ESMO Open
|
December 30, 2025
HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas
D M Filippini, B Cabarrou, C Dupain, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification
K Rahmani Narj Abadi, C Dupain, I Guillou, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 58) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 58 results.
ESMO Open
|
May 1, 2025
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)
R Galot, C Le Tourneau, L Licitra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 23, 2019
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages
C A Gomez-Roca, A Italiano, C Le Tourneau, et al.
ESMO Open
|
June 12, 2021
Prognostic value of tumor mutational burden in patients with oral cavity squamous cell carcinoma treated with upfront surgery
A Moreira, A Poulet, J Masliah-Planchon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 7, 2025
ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice
C B Westphalen, L Boscolo Bielo, P Aftimos, et al.
British Journal of Cancer
|
April 26, 2014
Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial
C Le Tourneau, X Paoletti, N Servant, et al.
ESMO Open
|
April 17, 2021
Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial
E de Guillebon, M Jimenez, L Mazzarella, et al.
ESMO Open
|
December 30, 2025
HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas
D M Filippini, B Cabarrou, C Dupain, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification
K Rahmani Narj Abadi, C Dupain, I Guillou, et al.
Page
of 6